Lung toxicity of lomustine in the treatment of progressive gliomas.

Corinna SeligerChristina NürnbergWolfgang WickAntje Wick

Published in: Neuro-oncology advances (2022)

Our findings support to limit lung function analyses on CCNU to patients with gliomas and pulmonary risk factors. However, all patients should be closely followed for clinical symptoms of pulmonary restriction.

Keyphrases

lung function
risk factors
pulmonary hypertension
high grade
end stage renal disease
cystic fibrosis
chronic obstructive pulmonary disease
ejection fraction
newly diagnosed
multiple sclerosis
oxidative stress
patient reported outcomes
physical activity
sleep quality
smoking cessation